Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer - PubMed
3 hours ago
- #RET fusion-positive NSCLC
- #pralsetinib efficacy
- #cancer treatment safety
- Final data from the ARROW study show pralsetinib (400 mg daily) is effective in advanced RET fusion-positive NSCLC, with an overall response rate of 78% in treatment-naïve patients and 63% in previously treated patients.
- Median overall survival was 44.3 months overall, 50.1 months in treatment-naïve patients, and 39.7 months in prior platinum-based chemotherapy patients, indicating durable benefits.
- Safety profile remained manageable with common grade ≥3 adverse events including anemia (21%), hypertension (15%), and decreased neutrophils (13%); three treatment-related deaths occurred, but no hypersensitivity was reported in patients with prior immunotherapies.